Powered by live-cell
super-resolution imaging

Pushing the boundaries of single-molecule imaging in living cells for drug discovery

Who we are

Mizar Therapeutics is a platform therapeutics company using proprietary live-cell single-molecule imaging and machine-learning technology for discovery of a new class of targeted cancer therapies.

Platform

Our platform consists of two intertwined elements: live-cell super-resolution imaging and AI-powered data extraction.

Our goal: to identify effective condensate modulators for novel targeted cancer therapeutics.

Condensates compartmentalizing proteins and nucleic acids are often the location of dysregulation in cancer, and the pharmocodynamics of cancer therapeutics can be affected by condensates.

We deploy our live-cell super-resolution technology to determine the interaction of lead compounds and condensate components in intact cells. Our imaging at high-frequency and over extended durations gives us unparalleled input data for our machine learning algorithms, meaning novel insight into hit discovery, hit-to-lead, target identification, mode of action and lead optimization.

Pipeline
Target class
Target Activity
Discovery
Hit-to-lead
IND-enabling
Phase 1/2
Market size
Hit-to-lead
Kinase
Oncogenic TK signaling
$3.0 B
Discovery
Kinase
Oncogenic TK signaling
$1.6 B
Discovery
Transcription factor
Oncogenic gene transcription
Rare disease
Our Advantage

Faster

High-frequency image capture rates

Longer

Extended durations: minutes, hours, even days

Gentler

Without damage or artifacts unlike other super-res systems = Ultra-rich protein behavior data for AI analysis

Breakthrough

Unprecedented platform for discovery

Contact us

Development inquiries to
bd@mizartx.com

Or contact us using the form (required fields indicated by *).

              arrow_upward